297 related articles for article (PubMed ID: 12212773)
1. Statin therapy for Alzheimer's disease: will it work?
Petanceska SS; DeRosa S; Olm V; Diaz N; Sharma A; Thomas-Bryant T; Duff K; Pappolla M; Refolo LM
J Mol Neurosci; 2002; 19(1-2):155-61. PubMed ID: 12212773
[TBL] [Abstract][Full Text] [Related]
2. Statins: drugs for Alzheimer's disease?
Eckert GP; Wood WG; Müller WE
J Neural Transm (Vienna); 2005 Aug; 112(8):1057-71. PubMed ID: 15682268
[TBL] [Abstract][Full Text] [Related]
3. Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain.
Kurata T; Kawai H; Miyazaki K; Kozuki M; Morimoto N; Ohta Y; Ikeda Y; Abe K
J Neurol Sci; 2012 Nov; 322(1-2):59-63. PubMed ID: 22795384
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease.
Kurata T; Miyazaki K; Kozuki M; Morimoto N; Ohta Y; Ikeda Y; Abe K
Neurol Res; 2012 Jul; 34(6):601-10. PubMed ID: 22732109
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
Kurata T; Miyazaki K; Kozuki M; Panin VL; Morimoto N; Ohta Y; Nagai M; Ikeda Y; Matsuura T; Abe K
Brain Res; 2011 Jan; 1371():161-70. PubMed ID: 21112317
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol and Alzheimer's disease: a still poorly understood correlation.
Ricciarelli R; Canepa E; Marengo B; Marinari UM; Poli G; Pronzato MA; Domenicotti C
IUBMB Life; 2012 Dec; 64(12):931-5. PubMed ID: 23124820
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain.
Butterfield DA; Barone E; Di Domenico F; Cenini G; Sultana R; Murphy MP; Mancuso C; Head E
Int J Neuropsychopharmacol; 2012 Aug; 15(7):981-7. PubMed ID: 21767440
[TBL] [Abstract][Full Text] [Related]
8. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.
Höglund K; Blennow K
CNS Drugs; 2007; 21(6):449-62. PubMed ID: 17521225
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin and Aβ(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease.
Butterfield DA
Exp Neurol; 2011 Mar; 228(1):15-8. PubMed ID: 21192930
[No Abstract] [Full Text] [Related]
10. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.
Zhang YY; Fan YC; Wang M; Wang D; Li XH
Clin Interv Aging; 2013; 8():103-10. PubMed ID: 23386786
[TBL] [Abstract][Full Text] [Related]
11. The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain.
Cibickova L; Hyspler R; Micuda S; Cibicek N; Zivna H; Jun D; Ticha A; Brcakova E; Palicka V
Steroids; 2009 Jan; 74(1):13-9. PubMed ID: 18817797
[TBL] [Abstract][Full Text] [Related]
12. Statins and dementia.
Kuller LH
Curr Atheroscler Rep; 2007 Aug; 9(2):154-61. PubMed ID: 17877925
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin.
Lu F; Li X; Suo AQ; Zhang JW
Chin Med J (Engl); 2010 Jul; 123(14):1864-70. PubMed ID: 20819569
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
[TBL] [Abstract][Full Text] [Related]
16. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
[TBL] [Abstract][Full Text] [Related]
17. Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease.
Höglund K; Wallin A; Blennow K
Acta Neurol Scand Suppl; 2006; 185():87-92. PubMed ID: 16866916
[TBL] [Abstract][Full Text] [Related]
18. [Effects of atorvastatin in multiple sclerosis].
Koh CS
Nihon Rinsho; 2003 Aug; 61(8):1455-60. PubMed ID: 12962038
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
20. Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Barbosa SP; Lins LC; Fonseca FA; Matos LN; Aguirre AC; Bianco HT; Amaral JB; França CN; Santana JM; Izar MC
Life Sci; 2013 May; 92(14-16):845-51. PubMed ID: 23507424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
